Sage Therapeutics Inc. [SAGE] gets an upgrade to a Buy from Guggenheim
Guggenheim took its Sage Therapeutics Inc. [NASDAQ:SAGE] rating to the equivalent of Buy from Neutral, in a research note dated January 4, 2021. Other analysts also revised their coverage, with Mizuho’s analysts upgrading the shares from “a Neutral” rating to “a Buy” rating in a research note to investors issued in early December. Meanwhile, Raymond […]